Loading
A phase 3 trial testing D-0502 in HR-positive / HER2-negative breast cancer, now recruiting.
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT06954961, led by InventisBio, and recruiting on the registry. Official title: A Randomised, Parallel-controlled, Open-label, Multicenter Phase III Clinical Study to Compare the Efficacy and Safety of D-0502 With Fulvestrant in Patients With Previously Treated ER-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer. Planned enrolment is 640 participants (estimated). The study started in 2022-09-15 and primary completion is expected in 2026-11-30. No results have been posted on ClinicalTrials.gov.